» Articles » PMID: 31591672

Transparency in Health Economic Modeling: Options, Issues and Potential Solutions

Overview
Specialty Pharmacology
Date 2019 Oct 9
PMID 31591672
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Economic models are increasingly being used by health economists to assess the value of health technologies and inform healthcare decision making. However, most published economic models represent a kind of black box, with known inputs and outputs but undisclosed internal calculations and assumptions. This lack of transparency makes the evaluation of the model results challenging, complicates comparisons between models, and limits the reproducibility of the models. Here, we aim to provide an overview of the possible steps that could be undertaken to make economic models more transparent and encourage model developers to share more detailed calculations and assumptions with their peers. Scenarios with different levels of transparency (i.e., how much information is disclosed) and reach of transparency (i.e., who has access to the disclosed information) are discussed, and five key concerns (copyrights, model misuse, confidential data, software, and time/resources) pertaining to model transparency are presented, along with possible solutions. While a shift toward open-source models is underway in health economics, as has happened before in other research fields, the challenges ahead should not be underestimated. Importantly, there is a pressing need to find an acceptable trade-off between the added value of model transparency and the time and resources needed to achieve such transparency. To this end, it will be crucial to set incentives at different stakeholder levels. Despite the many challenges, the many benefits of publicly sharing economic models make increased transparency a goal worth pursuing.

Citing Articles

Cost-effectiveness of Ezetimibe plus statin lipid-lowering therapy: A systematic review and meta-analysis of cost-utility studies.

Sasidharan A, Bagepally B, Sajith Kumar S, Jagadeesh K, Natarajan M PLoS One. 2022; 17(6):e0264563.

PMID: 35709152 PMC: 9202874. DOI: 10.1371/journal.pone.0264563.


Putting Stakeholder Engagement at the Center of Health Economic Modeling for Health Technology Assessment in the United States.

Xie R, Malik E, Linthicum M, Bright J Pharmacoeconomics. 2021; 39(6):631-638.

PMID: 33982198 PMC: 8166701. DOI: 10.1007/s40273-021-01036-3.


Development of a pharmacoeconomic registry: an example using hormonal contraceptives.

White A, Srinivasan M, Wingate L, Peasah S, Fleming M Health Econ Rev. 2021; 11(1):10.

PMID: 33745016 PMC: 7981865. DOI: 10.1186/s13561-021-00309-z.


A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer.

Gao W, Muston D, Monberg M, McLaurin K, Hettle R, Szamreta E Pharmacoeconomics. 2020; 38(11):1201-1218.

PMID: 32794041 PMC: 7547040. DOI: 10.1007/s40273-020-00949-9.


Novel Treatment Strategies for Secondary Prevention of Cardiovascular Disease: A Systematic Review of Cost-Effectiveness.

Marquina C, Zomer E, Vargas-Torres S, Zoungas S, Ofori-Asenso R, Liew D Pharmacoeconomics. 2020; 38(10):1095-1113.

PMID: 32583316 DOI: 10.1007/s40273-020-00936-0.


References
1.
Poole C, Agrawal S, Currie C . Let cost effectiveness models be open to scrutiny. BMJ. 2007; 335(7623):735. PMC: 2018758. DOI: 10.1136/bmj.39360.379664.BE. View

2.
Bierer B, Crosas M, Pierce H . Data Authorship as an Incentive to Data Sharing. N Engl J Med. 2017; 376(17):1684-1687. DOI: 10.1056/NEJMsb1616595. View

3.
Incerti D, Curtis J, Shafrin J, Lakdawalla D, Jansen J . A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis. Pharmacoeconomics. 2019; 37(6):829-843. DOI: 10.1007/s40273-018-00765-2. View

4.
Dunlop W, Mason N, Kenworthy J, Akehurst R . Benefits, Challenges and Potential Strategies of Open Source Health Economic Models. Pharmacoeconomics. 2016; 35(1):125-128. PMC: 5209409. DOI: 10.1007/s40273-016-0479-8. View

5.
Padula W, Brett McQueen R, Pronovost P . Finding Resolution for the Responsible Transparency of Economic Models in Health and Medicine. Med Care. 2017; 55(11):915-917. DOI: 10.1097/MLR.0000000000000813. View